molecular diagnostics companies bay area

In 2020, there were three deals totaling more than $1 billion, all in the liquid biopsy space: Illumina's $8 billion acquisition of Grail, which has faced pushback from regulators in the US and Europe Exact Sciences' acquisition of Thrive Earlier Detection for $2.2 billion and Invitae's $1.4 billion merger with ArcherDx. While there have been many smaller, tuck-in deals for less than $100 million, two significant acquisitions in the first half of the year totaled more than $1 billion: Roche's acquisition of GenMark for $1.8 billion and DiaSorin's acquisition of Luminex for $1.8 billion, also in April. Only acquisitions of an entire company were included. Included in the analysis are deals in the molecular and non-molecular in vitro diagnostic spaces that were announced or completed this past year. Part of the reason for the uptick in deals is the result of increased investor interest in molecular diagnostics and point-of-care testing due to the coronavirus pandemic, along with continued interest in early cancer detection and liquid biopsy. Through the first six months of the year, 39 M&A deals have been announced or completed in the Dx space putting it on pace to eclipse the 54 deals done for all of 2020, as well as the most recent high of 58 deals in 2017. NEW YORK – As the COVID-19 pandemic has resulted in more eyes on the diagnostics industry, major players and midsize companies alike have developed a case of mergers-and-acquisitions fever.

Molecular diagnostics companies bay area